<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">893</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2017-16-4-46-54</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">In silico and in vitro research of potential antineoplastic amino acid derivatives of indolocarbazol glycosides properties</article-title><trans-title-group xml:lang="ru"><trans-title>Изучение свойств потенциальных противоопухолевых аминокислотных производных гликозидов индолокарбазолов in silico и in vitro</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Apryshko</surname><given-names>G. N.</given-names></name><name xml:lang="ru"><surname>Апрышко</surname><given-names>Г. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zhukova</surname><given-names>O. S.</given-names></name><name xml:lang="ru"><surname>Жукова</surname><given-names>О. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fetisova</surname><given-names>L. V.</given-names></name><name xml:lang="ru"><surname>Фетисова</surname><given-names>Л. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vlasenkova</surname><given-names>N. K.</given-names></name><name xml:lang="ru"><surname>Власенкова</surname><given-names>Н. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pugacheva</surname><given-names>R. B.</given-names></name><name xml:lang="ru"><surname>Пугачева</surname><given-names>Р. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Goryunova</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Горюнова</surname><given-names>О. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>o.goryunova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology</institution></aff><aff><institution xml:lang="ru">ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-12-30" publication-format="electronic"><day>30</day><month>12</month><year>2017</year></pub-date><volume>16</volume><issue>4</issue><fpage>46</fpage><lpage>54</lpage><history><date date-type="received" iso-8601-date="2018-04-10"><day>10</day><month>04</month><year>2018</year></date></history><permissions/><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/893">https://bioterapevt.abvpress.ru/jour/article/view/893</self-uri><abstract xml:lang="en"><p>Objective: to evaluate the prospects of the glycosides of indolocarbazole containing amino acid residues as potential antitumor compounds. Materials and methods. For 32 compounds by structural formulas using the methods of chemoinformatics, a number of molecular descriptors and the probability of manifestation of various types of biological activity were calculated, the cytotoxic activity was evaluated in vitro by methylthiazole tetrazolium (MTT) assay using five human tumor cell lines. Results. For the studied amino acid derivatives of glycosides of indolocarbazole, a high probability of antitumor activity with a low probability of cytotoxic activity in vitro is predicted by computer method. Low cytotoxic activity was confirmed in the MTT test on 5 cell lines. Computer methods were used to predict the mechanisms of possible antitumor activity and to calculate a number of molecular descriptors that are important for the qualification of substances as potential drugs. Conclusion. It is expedient to study the antitumor activity of amino-acid derivatives of glycosides of indolocarbazole in experiments on animals with transplanted tumors.</p></abstract><trans-abstract xml:lang="ru"><p>Цель работы - оценка перспективности производных гликозидов индолокарбазола, содержащих аминокислотные остатки, как потенциальных противоопухолевых соединений. Материалы и методы. Для 32 соединений по структурным формулам с использованием методов хемоинформатики рассчитали ряд молекулярных дескрипторов и вероятность проявления различных видов биологической активности, в экспериментах in vitro оценили цитотоксическую активность с помощью МТТ-теста на 5 линиях клеток. Результаты. Для изученных аминокислотных производных гликозидов индолокарбазола компьютерным методом предсказана высокая вероятность противоопухолевой активности при низкой вероятности цитотоксической активности in vitro. Низкая цитотоксическая активность подтверждена в МТТ-тесте на 5 линиях клеток. Компьютерными методами получен прогноз механизмов возможной противоопухолевой активности и рассчитан ряд молекулярных дескрипторов, имеющих значение для квалификации веществ как потенциальных лекарств. Заключение. Целесообразно дальнейшее исследование противоопухолевой активности аминокислотных производных гликозидов индолокарбазола в опытах на животных с перевиваемыми опухолями.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гликозид индолокарбазолов</kwd><kwd>аминокислотное производное</kwd><kwd>противоопухолевая активность</kwd><kwd>цитотоксичность</kwd><kwd>прогнозирование биологической активности</kwd><kwd>glycoside of indolocarbazoles</kwd><kwd>amino acid derivative</kwd><kwd>antitumor activity</kwd><kwd>cytotoxicity</kwd><kwd>prediction of biological activity</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Konlker H.J., Reddy K.R. Isolation and synthesis of biologically active carbazole alkaloids. Chem Rev 2002; 102(11): 4303-427. PMID: 12428991.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Prudhomme M. Recent developments of rebeccamycin analogues as topoisom-erase I inhibitors and antitumor agents. Med Chem 2000; 7(12): 1189-212. PMID: 11032967.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Meng L.H., Liao Z.Y., Pommier Y. Non-camptothecin DNA topoisome-rase I inhibitors in cancer therapy. Curr Top Med Chem 2003; 3(3): 305-20. PMID: 12570765.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Pereira E.R., Fabre S., Sanselme M. et al. Antimicrobial activities of indolocarbazole and bis-indole protein kinase C inhibitors. II. Substitution on maleimide nitrogen with functional groups bearing a labile hydrogen. J Antibiot (Tokyo) 1995; 48(8): 863-8. PMID: 7592032.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Sielecki T.M., Boylan J.F., Benfield P.A., Trainor G.L. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J Med Chem 2000; 43(1): 1-18. PMID: 10633033.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Butler M.S. Natural products to drugs: natural product derived compounds in clinical trials. Nat Prod Rep 2005; 22(2): 162-95. DOI: 10.1039/ b402985m. PMID: 15806196.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Civenni G., Longoni N., Costales P. et al. EC-70124, a novel glycosylated in-dolocarbazole multikinase inhibitor, reverts tumorigenic and stem cell properties in prostate cancer by inhibiting STAT3 and NF-kB. Mol Cancer Ther 2016; 15(5): 806-18. DOI: 10.1158/15357163.MCT-15-0791. PMID: 26826115.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Shaaban K.A., Elshahawi S.I., Wang X. et al. Cytotoxic indolocarbazoles from Actinomadura melliaura ATCC 39691. J Nat Prod 2015; 78(7): 1723-9. DOI: 10.1021/acs.jnatprod.5b00429. PMID: 26091285.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Steinert G., Taylor M.W., Schup P.J. Diversity of Actinobacteria associated with the marine Ascidian Eudistoma toealen-sis. Mar Biotechnol 2015; 17(4): 377-85. DOI: 10.1007/s10126-015-9622-3. PMID: 25678260.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Prudhomme M. Biological targets of antitumor indolocarbazoles bearing a sugar moiety. Curr Med Chem Anticancer Agents 2004; 4(6): 509-21. PMID: 15579016.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Pindur U., Kim Y-S., Mehrabani F. Advances in indolo[2,3-a]carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Curr Med Chem 1999; 6(1): 29-69. PMID: 9873114.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Trostmann U., Hartenstein J., Barth H. et al. Патент Германии Ger. Offen DE 4243321 А1, June 23, 1994.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Trostmann U., Schaechtele C., Hartenstein J. et al. Патент США 5750555, May 12, 1998.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Горюнова О.В., Захарчук Г.М., Жукова О.С. и др. №-дипептидные производные Ш2-рибозил-индоло[2,3-а] карбазола. Биоорганическая химия 2014; 40(1): 12-9. DOI: 10.7868/S0132342314010047.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Omura S., Sasaki Y., Iwai Y., Takeshima H. Staurosporine, a potentially important gift from a microorganism. J Antibiot 1995; 48(7): 535-48. PMID: 7649849.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Апрышко Г.Н. Свидетельство о государственной регистрации базы данных «Противоопухолевые отечественные вещества, изученные в РОНЦ им. Н.Н. Блохина РАМН» № 2013620860. М.: Федеральная служба по интеллектуальной собственности, 29 июля 2013 г.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Филимонов Д.А., Поройков В.В. Прогноз спектра биологической активности органических соединений. Российский химический журнал 2006; 50(2): 66-75.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Filimonov D.A., Poroikov V.V. Probabilistic approach in activity prediction. In book: Chemoinformatics approaches to virtual screening. Eds.: A. Varnek, A. Tropsha. Cambridge (UK): RSC Publishing, 2008. Pp. 182-216.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Филимонов Д.А., Лагунин А.А., Глориозова Т.А. и др. Предсказание спектров биологической активности органических соединений с помощью веб-ресурса PASS Online. Химия гетероциклических соединений 2014; 3: 483-99.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Trepalin S.V., Yarkov A.V. CheD: chemical database compilation tool, internet server, and client for sql servers. J Chem Inf Comput Sci 2001; 41(1): 100-7. PMID: 11206361. http://www.vcclab.org/lab/alogps.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Трещалина Е.М., Жукова О.С., Герасимова Г.К. и др. Методические рекомендации по доклиническому изучению противоопухолевой активности лекарственных средств. В кн.: Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К, 2012. С. 642-656.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65(1-2): 55-63. PMID: 6606682.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Lipinski C.A., Lombardo F., Dominy B.W., Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 2001; 46(1-3): 3-26. PMID: 11259830.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Кубиньи Г. В поисках новых соединений-лидеров для создания лекарств. Российский химический журнал 2006; 50(2): 5-17.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Veber D.F., Johnson S.R., Cheng H.Y. et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002; 45(12): 2615-23. DOI: 10.1021/jm020017n. PMID: 12036371.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Omran Z., Rauch C. Acid-mediated Lipinski’s second rule: application to drug design and targeting in cancer. Eur Biophys J 2014; 43(4-5): 199-206. DOI: 10.1007/s00249-014-0953-1. PMID: 24687685.</mixed-citation></ref></ref-list></back></article>
